VolitionRX (VNRX) Corporate presentation summary

Recent achievements and milestones

• Cat paper submitted; if published, triggers a $5 million milestone payment. Fujifilm Vet Systems launched on automated i10 platform.

• Expansion into non-sepsis disease areas, including trauma and hidradenitis suppurativa, with Mayo Clinic publication and KOL preprint.

• Demonstrated utility of rapid, point-of-care finger-prick test in sepsis patients; DETECSEPS on track for first patient in Q3 2026.

• Certification completed at three French hospitals; reimbursement submission in preparation.

• Co-marketing agreement in place with Hologic; larger scale programs in confidential discussions.

Business model and commercialization strategy

• Asset-light, low-capex, low-opex model focused on commercial partnerships and out-licensing.

• Monetizes IP through upfront, milestone, and recurring revenue from licensing agreements.

• Broad geographic reach and large installed base through partnerships.

• Validated commercialization approach with Nu.Q Vet, targeting multiple licensing deals in human diagnostics.

Product portfolio and validation

• Nu.Q Vet available in North America, Europe, and Asia; detects 76% of systemic cancers at 97% specificity.

• Nu.Q Cancer addresses all five applications of blood tests in lung cancer, with reimbursement dossier in preparation.

• Capture-Seq enables world-first isolation of 99% pure tumor-associated DNA from liquid biopsy.

• Nu.Q NETs targets sepsis and other inflammatory diseases, with CE Mark/FDA status and first sales in EU.